Instagram Ern-EyeFacebook Ern-EyeTwitter Ern-EyeLinkedIn Ern-EyeYouTube Ern-EyeHow to use the speech recognition tool?
NCT03328130
Safety and Efficacy of a Unilateral Subretinal Administration of HORA-PDE6B in Patients With Retinitis Pigmentosa Harbouring Mutations in the PDE6B Gene Leading to a Defect in PDE6B Expression
Safety and Efficacy of a Unilateral Subretinal Administration of HORA-PDE6B in Patients With Retinitis Pigmentosa Harbouring Mutations in the PDE6B Gene Leading to a Defect in PDE6B Expression
Type: Interventional
Status of the trial: Active, Recruiting
Orphan Drug Recognition: Yes
Inclusion
- Opening Date: 2017-11-06
- Closing Date: 2020-06-30
Criteria
Inclusion: age ≥ 18 years ; clinical and molecular diagnosis of retinitis pigmentosa caused by defect in PDE6B gene without other syndromic manifestations
Children: No
Adults: Yes
Funder Type: industry
HCP: Principal investigators
HCP: Other investigators
Within ERN-EYE members
Workgroups
Retinal Rare Eye Diseases (WG1)
This ERN is supported by:
